Search research articles
Contact Us
Filters
Showing results (11-20 of 36) with videos related to
Page
of 4
Sort By:
Cancer Management and Research
|
August 8, 2022
Profile of Glasdegib for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML): Evidence to Date
Sunil Girish Iyer, Michele Stanchina, Terrence J Bradley, et al.
Leukemia Research Reports
|
November 7, 2022
The treatment of acute lymphoblastic leukemia in Jehovah's Witnesses and patients who cannot accept blood products
Nina Nguyen, Ellen Madarang, Alvaro Alencar, et al.
Leukemia Research Reports
|
August 21, 2025
Intercurrent presentation of hairy cell leukemia and diffuse large B-cell lymphoma with hemophagocytic lymphohistiocytosis: a case report
Tiffany Nong, Xiaoqiong Wang, Wenhui Li, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
September 25, 2004
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in corticobasal degeneration
Alexander Gerhard, Justin Watts, Iris Trender-Gerhard, et al.
Cancers
|
September 9, 2022
Functional Drug Screening of Small Molecule Inhibitors of Epigenetic Modifiers in Refractory AML Patients
Jessica L Dennison, Hassan Al-Ali, Claude-Henry Volmar, et al.
Leukemia Research Reports
|
June 2, 2020
Spontaneous remission of acute myeloid leukemia with NF1 alteration
Terrence Bradley, Radames Adamo Zuquello, Luis E Aguirre, et al.
Ejhaem
|
December 5, 2022
Molecular characteristics and outcomes in Hispanic and non-Hispanic patients with acute myeloid leukemia
Terrence Bradley, Deukwoo Kwon, Jorge Monge, et al.
Cancers
|
November 13, 2021
Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436
Fatih M Uckun, Justin Watts, Alice S Mims, et al.
Frontiers in Oncology
|
January 31, 2022
<i>Post-hoc</i> Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA
Justin Watts, Tara L Lin, Alice Mims, et al.
Cancers
|
August 27, 2021
A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Fatih M Uckun, Tara L Lin, Alice S Mims, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 36) with videos related to
Sort By:
Page
of 4
Cancer Management and Research
|
August 8, 2022
Profile of Glasdegib for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML): Evidence to Date
Sunil Girish Iyer, Michele Stanchina, Terrence J Bradley, et al.
Leukemia Research Reports
|
November 7, 2022
The treatment of acute lymphoblastic leukemia in Jehovah's Witnesses and patients who cannot accept blood products
Nina Nguyen, Ellen Madarang, Alvaro Alencar, et al.
Leukemia Research Reports
|
August 21, 2025
Intercurrent presentation of hairy cell leukemia and diffuse large B-cell lymphoma with hemophagocytic lymphohistiocytosis: a case report
Tiffany Nong, Xiaoqiong Wang, Wenhui Li, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
September 25, 2004
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in corticobasal degeneration
Alexander Gerhard, Justin Watts, Iris Trender-Gerhard, et al.
Cancers
|
September 9, 2022
Functional Drug Screening of Small Molecule Inhibitors of Epigenetic Modifiers in Refractory AML Patients
Jessica L Dennison, Hassan Al-Ali, Claude-Henry Volmar, et al.
Leukemia Research Reports
|
June 2, 2020
Spontaneous remission of acute myeloid leukemia with NF1 alteration
Terrence Bradley, Radames Adamo Zuquello, Luis E Aguirre, et al.
Ejhaem
|
December 5, 2022
Molecular characteristics and outcomes in Hispanic and non-Hispanic patients with acute myeloid leukemia
Terrence Bradley, Deukwoo Kwon, Jorge Monge, et al.
Cancers
|
November 13, 2021
Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436
Fatih M Uckun, Justin Watts, Alice S Mims, et al.
Frontiers in Oncology
|
January 31, 2022
<i>Post-hoc</i> Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA
Justin Watts, Tara L Lin, Alice Mims, et al.
Cancers
|
August 27, 2021
A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Fatih M Uckun, Tara L Lin, Alice S Mims, et al.
Page
of 4